Skip to main content

Cluster Headaches News

FDA Approves Brekiya (dihydroergotamine mesylate) Injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

BRIDGEWATER, N.J., May 15, 2025 – Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved Brekiya (dihydr...

Too Often, ER Docs Don't Spot Migraines in Minority Kids

THURSDAY, Feb. 6, 2025 – Kids and teens can also get migraines, but Black and Hispanic children seen in ERs are more likely to have their condition go undiagnosed, new research shows. That's...

FDA Approves Emgality (galcanezumab-gnlm) for the Treatment of Episodic Cluster Headache

INDIANAPOLIS, June 04, 2019 – Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality (galcanezumab-gnlm) injection (300 mg) for the t...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Headache

Related drug support groups

prednisone, lithium, tizanidine, sumatriptan, Emgality, indomethacin, Imitrex, cyproheptadine, verapamil